Table 2 Estimates of factors associated with change in cJADAS over time in mixed-effects models in pre-intervention and Phase I implementation cohorts

Male Sex

−1.86 (−2.75,-0.97)

< 0.01

–

–

Non-white race

−1.17 (− 1.42,1.08)

0.08

–

–

Public insurance

0.78 (− 0.08,1.65)

0.08

–

–

Baseline cJADAS

0.48 (0.42,0.55)

< 0.01

0.34 (0.28,0.40)

< 0.01

Polyarticular disease

1.47 (0.52,2.42)

< 0.01

–

–

Incident diagnosis

2.53 (1.60,3.47)

< 0.01

0.83 (0.02,1.63)

0.04

Time (in months)

−0.11 (− 0.16,-0.05)

< 0.01

− 0.03 (− 0.07,0.00)

0.07

Incident diagnosis * time interaction^

− 0.24 (− 0.35,-0.11)

< 0.01

− 0.21 (− 0.29,-0.13)

< 0.01

Pain VAS ^#

0.99 (0.88,1.10)

< 0.01

0.76 (0.66,0.86)

< 0.01

Tender entheses count ^#

0.66 (0.51,-0.80)

< 0.01

0.14 (0.02,0.25)

0.02

Biologic use ^#

−1.48 (−2.21,-0.75)

< 0.01

−0.56 (− 1.06,-0.07)

0.02

DMARD use ^#

0.46 (−0.43,1.35)

0.31

–

–

Phase I cohort (vs pre-intervention)

0.73 (−0.08-,1.54)

0.66

–

–

Pre/post Phase I cohort * time interaction^

0.02 (−0.21,0.24)

0.16

–

–